Powerful Science Engineered to Disrupt Cancer, Not Life
For decades, most cancer treatments have used continuous inhibition, applying constant pressure to block tumor growth. While this can shrink tumors quickly, it gives cancer time to adapt and develop resistance. At Immuneering, we recognized the problem: predictable therapeutic pressure allows cancer to evolve. Our scientists developed Deep Cyclic Inhibitors, a new class of medicines designed to pulse faster than cancer’s adaptive mechanisms. This rhythmic approach disrupts the tumor’s ability to resist treatment while allowing healthy cells to recover between doses. The result is more durable tumor control and improved tolerability for patients.
Helping patients live longer and feel better during treatment
Immuneering’s Deep Cyclic Inhibitors are designed to extend survival and make cancer treatment more tolerable. By reducing many of the side effects seen with traditional therapies, our approach aims to help patients maintain their strength, energy, and day-to-day activities. We believe cancer care should prioritize both survival and quality of life throughout treatment.
Transforming cancer care. Together.
Immuneering is leading a new era in oncology. By challenging convention and designing therapies that adapt faster than cancer itself, we’re changing what survival looks like. Our science is built on a simple belief: nothing matters more than keeping patients alive and helping them thrive.